Ignyta Inc (RXDX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014254)
◆英語タイトル:Ignyta Inc (RXDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014254
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:73
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥36,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥73,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥109,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Ignyta Inc (Ignyta), formerly NexDx Inc is a drug manufacturing company that discovers, develops and commercializes new drugs targeting activated genes in cancer cells for the treatment of cancer patients. The company develops products using integrated therapeutic (Rx) and companion diagnostic (Dx) technology platform. Its clinical pipeline includes selective tyrosine kinase inhibitor of the TrkA, TrkB, TrkC, ROS1 and ALK protein and a small molecule inhibitor of BRAF, EGFR and RET. Ignyta’s other pipeline products comprise taladegib, a small molecule smoothened antagonist; RXDX-105, a small molecule multikinase inhibitor; and RXDX-106, a small molecule, pseudo-irreversible inhibitor of TYRO3, AXL and Mer. The company also develops trailblaze diagnostic programs. Ignytais headquartered in San Diego, California, the US.

Ignyta Inc (RXDX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ignyta Inc, Medical Devices Deals, 2011 to YTD 2017 10
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Ignyta Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Ignyta Acquires Four Oncology R&D Assets from Cephalon 12
Venture Financing 14
NexDx Raises US$5.5 Million In Series B Financing 14
Partnerships 15
Ignyta Enters into Research Agreement with Moffitt Cancer Center 15
Merger 16
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 16
Licensing Agreements 17
Ignyta Amends Licensing Agreement with Eli Lilly 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 19
Ignyta Enters into Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 20
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 22
Equity Offering 24
Ignyta Prices Public Offering of Shares for USD160 Million 24
Ignyta Raises USD88.4 Million in Public Offering of Shares 26
Ignyta Raises USD57.5 Million in Public Offering of Shares 28
Ignyta Raises USD30 Million in Private Placement of Shares 30
Ignyta Raises USD75 Million in Public Offering of Shares 31
Ignyta Raises USD42 Million in Private Placement of Shares 33
Ignyta Completes Public Offering Of Shares For US$55.2 Million 34
Ignyta Completes Private Placement Of Shares For US$7.8 Million 36
Ignyta Completes Private Placement Of Shares For US$46.2 Million 37
Acquisition 38
Ignyta Acquires Actagene Oncology 38
Ignyta Inc – Key Competitors 39
Ignyta Inc – Key Employees 40
Ignyta Inc – Locations And Subsidiaries 41
Head Office 41
Recent Developments 42
Strategy And Business Planning 42
Feb 23, 2016: Ignyta Announces Strategic Positioning that Focuses on Prioritized Pipeline 42
Jan 11, 2016: Ignyta Unveils “5X5” Goal and Announces 2016 Strategic Priorities 43
Financial Announcements 44
Nov 07, 2017: Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results 44
Aug 08, 2017: Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results 46
May 01, 2017: Ignyta Announces First Quarter 2017 Company Highlights and Financial Results 48
Mar 14, 2017: Ignyta Announces Full Year 2016 Company Highlights and Financial Results 50
Nov 07, 2016: Ignyta Announces Third Quarter 2016 Company Highlights and Financial Results 52
Aug 09, 2016: Ignyta Announces Second Quarter 2016 Company Highlights and Financial Results 53
May 10, 2016: Ignyta Announces First Quarter 2016 Company Highlights and Financial Results 55
Mar 14, 2016: Ignyta Announces 2015 Full Year Company Highlights and Financial Results 57
Corporate Communications 60
Dec 12, 2016: Ignyta appoints new board member 60
Dec 12, 2016: Ignyta Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals to Board of Directors 61
Product News 62
12/02/2016: Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting 62
11/15/2016: Ignyta Announces EAP Designation and CE Marking for its Trailblaze Pharos Clinical Trial Assay 63
Clinical Trials 64
Mar 03, 2017: Angsana’s RNA-based fusions cancer panel selected for Ignyta’s STARTRK2 clinical trial in Asia-Pacific 64
Feb 09, 2017: Ignyta’s Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery 65
Nov 29, 2016: Ignyta to Present Pre-clinical Data on Entrectinib at the 2016 EORTC-NCI-AACR Annual Meeting 67
Aug 31, 2016: Ignyta Announces Approval of an Investigational Device Exemption (IDE) for the Companion Diagnostic Assay to the STARTRK-2 Trial 68
Apr 17, 2016: Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting 69
Apr 07, 2016: Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Ignyta Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ignyta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ignyta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ignyta Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Ignyta Inc, Medical Devices Deals, 2011 to YTD 2017 10
Ignyta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Ignyta Acquires Four Oncology R&D Assets from Cephalon 12
NexDx Raises US$5.5 Million In Series B Financing 14
Ignyta Enters into Research Agreement with Moffitt Cancer Center 15
Ignyta And Infinity Oil & Gas Merge In Reverse Merger Transaction 16
Ignyta Amends Licensing Agreement with Eli Lilly 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 19
Ignyta Enters into Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 20
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 22
Ignyta Prices Public Offering of Shares for USD160 Million 24
Ignyta Raises USD88.4 Million in Public Offering of Shares 26
Ignyta Raises USD57.5 Million in Public Offering of Shares 28
Ignyta Raises USD30 Million in Private Placement of Shares 30
Ignyta Raises USD75 Million in Public Offering of Shares 31
Ignyta Raises USD42 Million in Private Placement of Shares 33
Ignyta Completes Public Offering Of Shares For US$55.2 Million 34
Ignyta Completes Private Placement Of Shares For US$7.8 Million 36
Ignyta Completes Private Placement Of Shares For US$46.2 Million 37
Ignyta Acquires Actagene Oncology 38
Ignyta Inc, Key Competitors 39
Ignyta Inc, Key Employees 40

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Ignyta Inc (RXDX)-製薬・医療分野:企業M&A・提携分析(Ignyta Inc (RXDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆